Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

Blood (2019) 134 (Supplement_1): 2691.

https://doi.org/10.1182/blood-2019-124529

Published: 2019

Journal Articles

Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report

Era L. Pogosova-Agadjanyan, Anna Moseley, Brent L. Wood, MD PhD, Frederick R. Appelbaum, Thomas Chauncey, I-Ming L. Chen, DVM, MS, Harry P. Erba, MD PhD, John E. Godwin, Min Fang, Kenneth J. Kopecky, Alan F. List, Megan Othus, Jerald P. Radich, Cheryl L. Willman, Soheil Meshinchi, Derek L. Stirewalt

Blood (2016) 128 (22): 2890.

https://doi.org/10.1182/blood.V128.22.2890.2890

Published: 2016

Journal Articles

Age-Related Changes in the Interaction of Acute Myeloid Leukemia with the Bone Marrow Microenvironment Correlate with Response to Treatment and Survival: A Role for L-Selectin

Joe C Huang, MD, Yifan Lu, B.S., Julia Sidorova, PhD, Sylvia Chien, Vivian Oehler, MD, Kenneth J Kopecky, PhD, Pamela S. Becker, MD PhD

Blood (2016) 128 (22): 5063.

https://doi.org/10.1182/blood.V128.22.5063.5063

Published: 2016

Journal Articles

Prognostic Significance Of NPM1 mutations In The Absence Of FLT3 -ITD in Older Patients With AML: A SWOG Report

Fabiana Ostronoff, MD, Megan Othus, PhD, Soheil Meshinchi, MD, PhD, John E. Godwin, MD, MS, Kenneth J. Kopecky, PhD, Alan List, MD, Vivian G. Oehler, MD, Stephen Petersdorf, MD, Era L. Pogosova-Agadjanyan, Jerald Radich, MD, Cheryl L. Willman, MD, Frederick R. Appelbaum, MD, Derek L. Stirewalt, MD

Blood (2013) 122 (21): 1315.

https://doi.org/10.1182/blood.V122.21.1315.1315

Published: 2013

Journal Articles

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

Stephen H. Petersdorf, Kenneth J. Kopecky, Marilyn Slovak, Cheryl Willman, Thomas Nevill, Joseph Brandwein, Richard A. Larson, Harry P. Erba, Patrick J. Stiff, Robert K. Stuart, Roland B. Walter, Martin S. Tallman, Leif Stenke, Frederick R. Appelbaum

Blood (2013) 121 (24): 4854–4860.

https://doi.org/10.1182/blood-2013-01-466706

Published: 2013

Journal Articles

Single-Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia (AML): Validation in Two Independent Sample Sets From ECOG and SWOG Trials.

Alessandra Cesano, M.D., Ph.D., Cheryl L Willman, MD, Kenneth J. Kopecky, PhD, Urte Gayko, Ph.D., Santosh Putta, Ph.D., Brent Louie, Ph.D., Matt Westfall, Ph.D., Norman Purvis, Ph.D., David Spellmeyer, PhD, Carol Marimpietri, James Hackett, Ph.D., Jing Shi, Elisabeth Paietta, PhD, Martin S. Tallman, MD, Larry D Cripe, MD, Susan K. Atwater, MD, Frederick R. Appelbaum, MD, Jerald P. Radich, MD

Blood (2012) 120 (21): 2489.

https://doi.org/10.1182/blood.V120.21.2489.2489

Published: 2012

Journal Articles

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia

Jerald P. Radich, Kenneth J. Kopecky, Frederick R. Appelbaum, Suzanne Kamel-Reid, Wendy Stock, Greg Malnassy, Elisabeth Paietta, Martha Wadleigh, Richard A. Larson, Peter Emanuel, Martin Tallman, Jeff Lipton, A. Robert Turner, Michael Deininger, Brian J. Druker

Blood (2012) 120 (19): 3898–3905.

https://doi.org/10.1182/blood-2012-02-410688

Published: 2012

Journal Articles

Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18–60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG

Era L. Pogosova-Agadjanyan, Kenneth J. Kopecky, PhD, Stephen Petersdorf, MD, Harry Paul Erba, MD, PhD, Richard M. Stone, MD, Soheil Meshinchi, MD, PhD, Thomas J. Nevill, MD, FRCPC, Jerald P. Radich, MD, Leif Stenke, MD, PhD, Marilyn L Slovak, PhD, Robert K Stuart, MD, Martin S. Tallman, MD, Cheryl L Willman, MD, Rebecca M. Mortensen, Breanna L. Wentz, Frederick R. Appelbaum, MD, Derek L. Stirewalt, MD

Blood (2011) 118 (21): 2520.

https://doi.org/10.1182/blood.V118.21.2520.2520

Published: 2011

Journal Articles

Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data

Laura F Newell, MD, Megan Othus, PhD, Roland B. Walter, MD, PhD, Stephen H. Petersdorf, MD, Thomas Chauncey, MD, PhD, Jeanne E. Anderson, MD, John E. Godwin, MD, MS, Kenneth J. Kopecky, PhD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2011) 118 (21): 1446.

https://doi.org/10.1182/blood.V118.21.1446.1446

Published: 2011

Journal Articles

Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG

Blood (2011) 118 (17): 4561–4566.

https://doi.org/10.1182/blood-2011-04-348888

Published: 2011

Includes: Supplemental data

Journal Articles

Clinical and Functional Relevance of Interactions Between the Bone Marrow Stormal Microenvironment and Primary Human Acute Myeloid Leukemia (AML) Cells

Soumit K. Basu, MD, PhD, Sylvia Chien, Xin Zhao, MD, Kenneth J. Kopecky, PhD, Frederick R. Appelbaum, MD, Thalia Papayannopoulou, MD, DSci, Elihu H. Estey, MD, Pamela S. Becker, MD, PhD

Blood (2010) 116 (21): 2756.

https://doi.org/10.1182/blood.V116.21.2756.2756

Published: 2010

Journal Articles

Over-Expression of Novel IRF8 Splice Variants Is Associated with a Significant Decrease In Relapse-Free Survival In Adult AML Patients.

Era L. Pogosova-Agadjanyan, Kenneth J. Kopecky, PhD, Hana Lee, Jeanne E. Anderson, MD, John E. Godwin, MD, MS, Alan F. List, Soheil Meshinchi, MD, PhD, Vivian Oehler, MD, Stephen H. Petersdorf, MD, Cheryl L. Willman, MD, Frederick R. Appelbaum, MD, Jerald P. Radich, MD, Derek L. Stirewalt, MD

Blood (2010) 116 (21): 1679.

https://doi.org/10.1182/blood.V116.21.1679.1679

Published: 2010

Journal Articles

A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial

Jerald P. Radich, MD, Kenneth J. Kopecky, PhD, Suzanne Kamel-Reid, PhD, Wendy Stock, MD, Elisabeth Paietta, PhD, Martha Wadleigh, MD, Richard A. Larson, MD, Peter D. Emanuel, MD, Martin S. Tallman, MD, Jeffrey Lipton, MD, FRCPC, Stephen Couban, BSc, MD, Michael W. Deininger, MD, PhD, Frederick R. Appelbaum, MD, Brian J. Druker, MD

Blood (2010) 116 (21): LBA-6.

https://doi.org/10.1182/blood.V116.21.LBA-6.LBA-6

Published: 2010

Journal Articles

Prognostic Implications of the IDH1 synonymous SNP rs11554137 In Pediatric and Adult AML: a Children's Oncology Group and Southwest Oncology Group Study

Blood (2010) 116 (21): 2737.

https://doi.org/10.1182/blood.V116.21.2737.2737

Published: 2010

Journal Articles

Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia

Pamela S. Becker, Kenneth J. Kopecky, Adrianne N. Wilks, Sylvia Chien, John M. Harlan, Cheryl L. Willman, Stephen H. Petersdorf, Derek L. Stirewalt, Thalia Papayannopoulou, Frederick R. Appelbaum

Blood (2009) 113 (4): 866–874.

https://doi.org/10.1182/blood-2007-12-124818

Published: 2009

Includes: Supplemental data

Journal Articles

Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study

Vinod Pullarkat, Marilyn L. Slovak, Kenneth J. Kopecky, Stephen J. Forman, Frederick R. Appelbaum

Blood (2008) 111 (5): 2563–2572.

https://doi.org/10.1182/blood-2007-10-116186

Published: 2008

Includes: Supplemental data

Journal Articles

Phase II Studies of Different Schedules and Doses of the Farnesyl Transferase Inhibitor Tipifarnib (R115777, Zarnestra, NSC-702818) for Patients of Age 70 or Older with Previously Untreated Acute Myeloid Leukemia (AML): A North American Intergroup Study (S0432).

Harry P. Erba, MD, PhD, Kenneth J. Kopecky, PhD, Mark H. Kirschbaum, MD, Martin S. Tallman, MD, Richard A. Larson, MD, Cheryl L. Willman, MD, Marilyn L. Slovak, PhD, Holly M. Gundacker, MA, Frederick R. Appelbaum, MD

Blood (2007) 110 (11): 440.

https://doi.org/10.1182/blood.V110.11.440.440

Published: 2007

Journal Articles

Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials

Nataliya Kuptsova, Kenneth J. Kopecky, John Godwin, Jeanne Anderson, Ashraful Hoque, Cheryl L. Willman, Marilyn L. Slovak, Christine B. Ambrosone

Blood (2007) 109 (9): 3936–3944.

https://doi.org/10.1182/blood-2006-05-022111

Published: 2007

Journal Articles

Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction

Blood (2006) 108 (2): 685–696.

https://doi.org/10.1182/blood-2004-12-4633

Published: 2006

Includes: Supplemental data

Journal Articles

Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia

Derek L. Stirewalt, Kenneth J. Kopecky, Soheil Meshinchi, Julia H. Engel, Era L. Pogosova-Agadjanyan, Jeremy Linsley, Marilyn L. Slovak, Cheryl L. Willman, Jerald P. Radich

Blood (2006) 107 (9): 3724–3726.

https://doi.org/10.1182/blood-2005-08-3453

Published: 2006

Includes: Supplemental data

NARROW

Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report

Age-Related Changes in the Interaction of Acute Myeloid Leukemia with the Bone Marrow Microenvironment Correlate with Response to Treatment and Survival: A Role for L-Selectin

Prognostic Significance Of NPM1 mutations In The Absence Of FLT3 -ITD in Older Patients With AML: A SWOG Report

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

Single-Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia (AML): Validation in Two Independent Sample Sets From ECOG and SWOG Trials.

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia

Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18–60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG

Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data

Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG

Clinical and Functional Relevance of Interactions Between the Bone Marrow Stormal Microenvironment and Primary Human Acute Myeloid Leukemia (AML) Cells

Over-Expression of Novel IRF8 Splice Variants Is Associated with a Significant Decrease In Relapse-Free Survival In Adult AML Patients.

A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial

Prognostic Implications of the IDH1 synonymous SNP rs11554137 In Pediatric and Adult AML: a Children's Oncology Group and Southwest Oncology Group Study

Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia

Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study

Phase II Studies of Different Schedules and Doses of the Farnesyl Transferase Inhibitor Tipifarnib (R115777, Zarnestra, NSC-702818) for Patients of Age 70 or Older with Previously Untreated Acute Myeloid Leukemia (AML): A North American Intergroup Study (S0432).

Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials

Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction

Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only